Samsrita Labs Ltd (SAMSRITA) — shareholding pattern, promoter holding, financials and share price
About Samsrita Labs Ltd (SAMSRITA)
Samsrita Labs Ltd operates in the Healthcare Service Provider industry, within the Healthcare sector. It trades on the NSE as SAMSRITA and on the BSE under scrip code 539267. Its ISIN is INE579N01018.
Incorporated in 1996, Samsarita Labs Ltd is in the business of healthcare services including hospital, diagnostics, Pharma, and Biotechnology (R&D)
Samsrita Labs Limited, formerly Dr Habeebullah Life Sciences Limited, is engaged in the bio-pharma sector focusing on drug discovery, stem cell therapy, and molecular diagnostics.
The company has transitioned from its initial focus on stem cell hospitals to include biopharma activities, emphasized by its historical changes in main business objects to incorporate advanced drug discovery and biotechnology research.
Listed peers in Healthcare Service Provider: N G Industries Ltd, Deccan Health Care Ltd, Sharma East India Hosp and Medical Research Ltd, Tejnaksh Healthcare Ltd, Chennai Meenakshi Multispeciality Hospital Ltd, Transgene Biotek Ltd.
Valuation & Returns
10 Jul 2026At ₹13.45 a share on 10 Jul 2026, Samsrita Labs Ltd (SAMSRITA) was valued at a price-to-earnings ratio of -3.7x against an industry P/E of 61.73x and a price-to-book of 2.56x on a book value of ₹5.26 per share as of Mar 2025. Solomo computes return on equity of -70.32% and return on capital employed of -58.47% from filed results. Earnings ratios use consolidated results for the twelve months Dec 2024 to Mar 2026.
- P/E
- -3.7x
- Industry P/E
- 61.73x
- P/B
- 2.56x
- EPS (TTM)
- ₹-3.7
- Book value / share
- ₹5.26
- ROE
- -70.32%
- ROCE
- -58.47%
- ROA
- -54.08%
- Debt / equity
- 0.2x
- Dividend yield
- 0%
- 52-week range
- ₹11.2 – ₹26.04
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Samsrita Labs Ltd (SAMSRITA) reported revenue of ₹0.02 crore, net profit of ₹-8.16 crore and earnings per share of ₹-3.59. Figures are consolidated, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹0.02 crore and net profit ₹-0.48 crore (consolidated).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 0.02 | 0.02 | 0 | 0 | 0.02 |
| Net profit (₹ cr) | 1.49 | -0.71 | -0.26 | -0.28 | -8.16 |
| EPS (₹) | 1.01 | -0.48 | -0.18 | -0.19 | -3.59 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Profit growth | - | - | - | -4.00% |
| Stock price CAGR | 6% | -16% | -7% | -26% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 25.44% of Samsrita Labs Ltd (SAMSRITA) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0% and domestic institutional investors (DII) hold 0%. Market capitalisation was ₹31 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Jun 2015.
Largest disclosed public shareholders in Jun 2026: Vase K B Christ 7.73%, Chopperla N P Ravikanth 7.1%, Ved Krishna Uppuluri 5.16%, Sarvothama Reddy Morramreddygari 3.34%, Siddarth Ravishankar Sarnaik 3.06%, M Neela Reddy 3.04%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 25.44% | - | 0% | 0% | 74.56% |
| Mar 2026 | 25.44% | - | 0% | 0% | 74.56% |
| Dec 2025 | 25.44% | - | 0% | 0% | 74.56% |
| Sep 2025 | 31.41% | - | 0% | 0% | 68.59% |
| Jun 2025 | 48.25% | - | 0% | 0% | 51.75% |
| Mar 2025 | 49.27% | - | - | - | 50.73% |
| Dec 2024 | 52.87% | - | - | - | 47.13% |
| Sep 2024 | 52.87% | 5.1% | - | - | 47.13% |